Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study

Indian Journal of Dermatology, Venereology and Leprology

Volumn 74, Issue 1, 2008, Pages 18-22

  Pareek, Anil ^a,d   Khopkar, Uday ^b   Sacchidanand, S ^c   Chandurkar, Nitin ^a   Naik, Geeta ^a  

^a IPCA Laboratories Ltd   (India)

^b KEM HOSPITAL   (India)

^c Victoria Hospital   (India)

^d Kandivli Industrial Estate ^*  (India)

Author keywords

Hydroxychloroquine; Photodermatosis; Polymorphic light eruption

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE;

ADULT; AGED; ARTICLE; BODY WEIGHT; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; EYE TOXICITY; FEMALE; GASTRITIS; HUMAN; HYPERPIGMENTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHOTODERMATOSIS; POLYMORPHIC LIGHT ERUPTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 38349028617     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.38401     Document Type: Article

References (19)

1. Ferguson J, Ibbotson SH. The idiopathic photodermatoses. Semin Cutan Med Surg 1999;18:257-73.
2. Epstein JH. Polymorphous light eruption. J Am Acad Dermatol 1980;3:329-43.
3. Nynberg F, Hasan T, Puska P, Stephansson E, Häkkinen M, Ranki A, et al. Occurrence of polymorphous light eruptions in lupus erythematosus. Br J Dermatol 1997;136:217-21.
4. Tutrone WD, Spann CT, Scheinfeld N, Deleo VA. Polymorphic light eruption. Dermatol Ther 2003;16:28-39.
5. Ling TC, Gibbs NK, Rhodes LE. Treatment of polymorphic light eruption. Photodermatol Photoimmunol Photomed 2003:19:217-27.
6. Murphy GM, Logan RA, Lovell CR, Morris RW, Hawk JL, Magnus IA. Prophylactic PUVA and UVB therapy in polymorphic light eruption - a controlled trial. Br J Dermatol 1987;116:531-8.
7. Bilsland D, George SA, Gibbs NK, Aitchison T, Johnson BE, Ferguson J. Comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol 1993;129:708-12.
8. Corbett MF, Hawk JLM, Herxheimer A, Magnus IA. Controlled therapeutic trials in polymorphic light eruption. Br J Dermatol 1982;107:571-81.
9. Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in Polymorphic light eruption: A controlled trial with drug and visual sensitivity monitoring. J Dermatol 1987;116:379-86.
10. Tobin DR. Hydroxychloroquine in light eruption: New indication. Prescrire Int 1999;8:72-3.
11. Holzle E, Plewig G, von Kries R, Lehmann P. Polymorphous light eruption. J Invest Dermatol 1987;88:32s-8s.
12. Jansen CT. The morphologic features of polymorphous light eruptions. Cutis 1980;26:164-7,169-70.
13. Epstein JH. Polymorphous light eruption. Photodermatol Photoimmunol Photomed 1997;13:89-90.
14. Patel DC, Bellaney GJ, Seed PT, McGregor JM, Hawk JL. Efficacy of short-course oral prednisolone in polymorphic light eruption: A randomized controlled trial. Br J Dermatol 2000;143:828-31.
15. Jones SK. Ocular toxicity and hydroxychloroquine: Guidelines for screening. Br J Dermatol 1999;140:3-7.
16. Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in Polymorphic light eruption: A controlled trial with drug and visual sensitivity monitoring. Br J Dermatol 1983;109:37.
17. Breckenridge A. Risks and benefits of prophylactic antimalarial drugs. BMJ 1989;299:1057-8.
18. Rynes RI, Krohel G, Falbo A, Reinecke RD, Wolfe B, Bartholomew LE. Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum 1979;22:832-6.
19. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985;12:692-4.